Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models
Open Access
- 28 July 2026
- journal article
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 2997-3006
Abstract
Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models. Here, we evaluated combining NAMPT inhibition with dietary nicotinic acid (NA) restriction to suppress NAR‐dependent NAD biosynthesis. This combination showed enhanced antitumor activity consistent with synthetic lethality in SCLC CDX models and showed robust efficacy in PDX models, including those derived from chemotherapy‐refractory tumors. In most CDX models examined, combination therapy showed greater antitumor activity than standard chemotherapy with cisplatin and etoposide. Although we did observe transient leukopenia, the treatment was otherwise better tolerated than chemotherapy, with less impact on body weight and platelet counts. These findings support NAD metabolism–targeted therapy as a promising strategy to treat SCLC.Keywords
Funding Information
- Japan Science and Technology Agency (JPMJCR2123)
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (22K08989)
- Japan Society for the Promotion of Science (23K07613)
- Japan Society for the Promotion of Science (23K08577)
- Japan Society for the Promotion of Science (23K18248)
- Japan Society for the Promotion of Science (23K27448)
- Japan Society for the Promotion of Science (25K12120)
- Japan Society for the Promotion of Science (26K02285)
- Japan Society for the Promotion of Science (JP23H04939)
- Japan Society for the Promotion of Science (JP23H04946)
- Japan Agency for Medical Research and Development (25ama221145h0001)
- Japan Agency for Medical Research and Development (25ama221145h0002)
- Japan Agency for Medical Research and Development (JP21zf0127001)
- Princess Takamatsu Cancer Research Fund
- Takeda Foundation
- Naito Foundation
This publication has 40 references indexed in Scilit:
- FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cellsJournal of Biological Chemistry, 2024
- Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulatorsCancer Cell, 2024
- Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeCancer Cell, 2024
- The hallmarks of cancer metabolism: Still emergingCell Metabolism, 2022
- A purine metabolic checkpoint that prevents autoimmunity and autoinflammationCell Metabolism, 2022
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCancer Cell, 2021
- An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype MappingCell, 2020
- Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancerFEBS Letters, 2020
- PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell GrowthCancer Cell, 2018
- NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the NucleusCell Metabolism, 2015